Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Add-on to metformin in T2DM—linagliptin or glimepiride?

Nature Reviews Endocrinology volume 8, pages 576–578 (2012)Cite this article

Subjects

Clinicians are responsible for selecting a suitable second-line treatment for patients with type 2 diabetes mellitus when metformin monotherapy fails. New evidence could aid clinicians in deciding between one of the most commonly used second-line agents, glimepiride, and the recently approved dipeptidyl peptidase 4 inhibitor linagliptin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gallwitz, B. et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 380, 475–483 (2012).

    Article  CAS  Google Scholar 

  2. Inzucchi, S. E. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55, 1577–1596 (2012).

    Article  CAS  Google Scholar 

  3. [No authors listed] U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44, 1249–1258 (1995).

  4. Maedler, K. et al. Sulfonylurea induced cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab. 90, 501–506 (2005).

    Article  CAS  Google Scholar 

  5. U.K. Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50, 1140–1147 (2007).

  6. Landstedt-Hallin, L., Adamson, U. & Lins, P. E. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 84, 3140–3145 (1999).

    CAS  PubMed  Google Scholar 

  7. Ahrén, B. et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 1236–1243 (2009).

    Article  Google Scholar 

  8. Sivertsen, J., Rosenmeier, J., Holst, J. J. & Vilsbøll, T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat. Rev. Cardiol. 9, 209–222 (2012).

    Article  CAS  Google Scholar 

  9. Engbersen, R. et al. Differential effects of sulfonylurea derivatives on vascular ATP-sensitive potassium channels. Eur. J. Pharmacol. 681, 75–79 (2012).

    Article  CAS  Google Scholar 

  10. Bonds, D. E. et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 340, b4909 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Bispebjerg Bakke 23, Copenhagen, 2400, Denmark

    Mikkel Christensen

  2. Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, DK-2900, Denmark

    Filip K. Knop

Authors
  1. Mikkel Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filip K. Knop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Filip K. Knop.

Ethics declarations

Competing interests

Filip K. Knop declares that he has received speakers bureau from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Sharp & Dohme, Novartis, Novo Nordisk and Ono Pharmaceuticals. Mikkel Christensen declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christensen, M., Knop, F. Add-on to metformin in T2DM—linagliptin or glimepiride?. Nat Rev Endocrinol 8, 576–578 (2012). https://doi.org/10.1038/nrendo.2012.163

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2012.163

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing